Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2861 - Detection of mutations and copy number alterations in circulating DNA from pancreatic neuroendocrine tumor patients

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Gitta Boons

Citation

Annals of Oncology (2018) 29 (suppl_8): viii467-viii478. 10.1093/annonc/mdy293

Authors

G. Boons1, K. Op de Beeck2, T. Vandamme2, M. Beyens3, G. Roeyen4, K. Janssens3, K. Zwaenepoel2, G. van Camp3, M. Peeters2

Author affiliations

  • 1 Mipro, University of Antwerp/Antwerp University Hospital, 2650 - Edegem/BE
  • 2 Mipro, University of Antwerp/Antwerp University Hospital, Edegem/BE
  • 3 Medgen, University of Antwerp/Antwerp University Hospital, Edegem/BE
  • 4 Hepatobiliary, Transplantation And Endocrine Surgery, Antwerp University Hospital, Edegem/BE
More

Resources

Abstract 2861

Background

Chromogranin A, the most frequently used circulating biomarker for diagnosis and follow-up of pancreatic neuroendocrine tumor (PNET) patients, has several limitations. Research in other tumor types has indicated the biomarker potential of circulating tumor DNA (ctDNA). However, ctDNA remains unexplored in PNETs. In this study, we aimed to detect and profile ctDNA in plasma of PNET patients.

Methods

Tumor tissue, perioperative blood samples and clinicopathological data were prospectively collected from 10 PNET patients undergoing surgery for their primary tumor at the Antwerp University Hospital. An additional blood sample was collected from one case during follow-up, when patient had disease progression. Whole exome sequencing was performed on tumor and germline DNA to identify somatic variants and copy number alterations (CNAs). For every patient a somatic single nucleotide variant (SNV) was selected and a digital droplet PCR assay was developed to detect this SNV in DNA isolated from plasma. Shallow whole genome sequencing (sWGS) was performed on plasma DNA to identify CNAs.

Results

In two patients, the somatic SNV could be detected in the perioperative plasma sample at variant allele fractions (VAFs) of 19% and 21%. Interestingly, both patients had metastatic disease and succumbed within two years after surgery, while the other eight patients presented with localized disease and are currently disease-free. The follow-up plasma sample of one of the positive cases showed an increase in VAF to 57%. Next, sWGS was performed on ctDNA-positive plasma to detect CNAs. A significant correlation (p < 0.01) was found between CNAs in primary tumor and CNAs in perioperative plasma sample. The CNA profile of the follow-up sample showed increased genetic instability.

Conclusions

We provide evidence for the presence of ctDNA in patients with a metastatic PNET. Non-metastatic cases were ctDNA-negative. An increase in VAF and genetic instability were found in the follow-up sample of one of the metastatic cases, suggesting potential for ctDNA as follow-up marker. Furthermore, CNAs in primary tumor and plasma sample were significantly correlated, proposing ctDNA as an alternative for molecular profiling of tissue in metastatic patients.

Clinical trial identification

Legal entity responsible for the study

Antwerp University Hospital.

Funding

Kom op tegen Kanker (Stand up to Cancer), the Flemish cancer society; Research Foundation – Flanders (FWO).

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings